Trevena 8/8/2024 Earnings Report $1.67 -0.02 (-0.89%) As of 01/31/2025 02:40 PM Eastern Earnings HistoryForecast Trevena EPS ResultsActual EPS-$0.23Consensus EPS -$9.25Beat/MissBeat by +$9.02One Year Ago EPSN/ATrevena Revenue ResultsActual Revenue$0.33 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATrevena Announcement DetailsQuarterDate8/8/2024TimeBefore Market OpensConference Call ResourcesTRVN Earnings History Trevena Earnings HeadlinesTrevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.comFebruary 1 at 2:45 AM | americanbankingnews.comTrevena (NASDAQ:TRVN) Stock Crosses Below Two Hundred Day Moving Average - Here's WhyJanuary 30 at 3:29 AM | americanbankingnews.comTrump’s “Shock and Awe” Executive OrderPresident Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn from the World Health Organization... exited the Paris climate accord... and begun dismantling many Federal programs... But there's ONE executive order that could go down in history as the most important of all.February 2, 2025 | Altimetry (Ad)JMP Securities downgrades Trevena (TRVN) to a HoldDecember 28, 2024 | markets.businessinsider.com‘Plane’ Actor Oliver Trevena Signs With Untitled EntertainmentDecember 16, 2024 | yahoo.comTrevena appoints new financial chiefNovember 29, 2024 | investing.comSee More Trevena Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Trevena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevena and other key companies, straight to your email. Email Address About TrevenaTrevena (NASDAQ:TRVN), a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.View Trevena ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
